Thomas Smith
Stock Analyst at Leerink Partners
(2.32)
# 2,568
Out of 4,945 analysts
67
Total ratings
29.51%
Success rate
14.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $0.98 | +2.03% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $1.88 | +378.72% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $1.69 | +314.20% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $4.39 | +560.59% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $11.67 | +234.19% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $8.67 | +199.88% | 1 | Mar 25, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $80 | $11.27 | +609.85% | 2 | Feb 21, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $69.56 | -71.25% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $652.43 | -33.33% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $60.73 | -40.72% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $2.15 | +225.58% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $15.20 | +38.16% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $18.46 | +143.77% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $7.49 | -19.89% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $3.70 | +62.16% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.92 | +445.55% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $54.77 | -68.96% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $24.94 | +156.62% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $17.57 | +298.41% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $29 | $9.11 | +218.33% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $2.60 | +900.00% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $40.24 | -70.18% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $4.11 | +143.31% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $3.29 | +12,058.05% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $14.41 | +455.17% | 2 | Dec 8, 2020 |
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.98
Upside: +2.03%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $1.88
Upside: +378.72%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $1.69
Upside: +314.20%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $4.39
Upside: +560.59%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $11.67
Upside: +234.19%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $8.67
Upside: +199.88%
RAPT Therapeutics
Feb 21, 2024
Downgrades: Market Perform
Price Target: $80
Current: $11.27
Upside: +609.85%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $69.56
Upside: -71.25%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $652.43
Upside: -33.33%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $60.73
Upside: -40.72%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $2.15
Upside: +225.58%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $15.20
Upside: +38.16%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $18.46
Upside: +143.77%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $7.49
Upside: -19.89%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $3.70
Upside: +62.16%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.92
Upside: +445.55%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $54.77
Upside: -68.96%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $24.94
Upside: +156.62%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $17.57
Upside: +298.41%
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $9.11
Upside: +218.33%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $2.60
Upside: +900.00%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $40.24
Upside: -70.18%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $4.11
Upside: +143.31%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $3.29
Upside: +12,058.05%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $14.41
Upside: +455.17%